黑石的创新药赌局

氨基观察
Nov 06, 2025

©氨基观察-创新药组原创出品作者 | 郑晓在引进科伦博泰的TROP-2 ADC药物sacituzumab tirumotecan后,默沙东可谓火力全开:截至目前,该药物已启动15项全球3期临床试验,入组患者规模达1.5万名,且未来临床布局可能进一步拓展。如此大规模的投入与布局,无疑表明了默沙东对TROP-2 ADC赛道的高度看好。正如默沙东高级副总裁兼肿瘤学全球临床开发负责人Marjorie ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10